Form 4: Vertex Pharmaceuticals EVP David Altshuler Reports Stock Sale
SEC Filing Form 4
David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, reported selling 54 shares of common stock on May 15, 2024, under a pre-arranged trading plan.
Summary
- David Altshuler, the EVP and Chief Scientific Officer of Vertex Pharmaceuticals, filed a Form 4 with the SEC.
- The form reports the sale of 54 shares of Vertex Pharmaceuticals common stock on May 15, 2024.
- The shares were sold at a price of $430.93 per share.
- Following the transaction, Altshuler directly owns 25,813 shares of Vertex Pharmaceuticals common stock.
- The sale was executed under a company-approved trading plan (Rule 10b5-1) established on May 10, 2023.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment towards the company's prospects.
Industry Context
Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their trading activities. The sale represents a small percentage of Altshuler's holdings.
Stakeholder Impact
- The impact on shareholders is likely minimal, given the small size of the transaction relative to the company's overall market capitalization.
Key Dates
| Date | Description |
|---|---|
| 05/10/2023 | Date of entry into Rule 10b5-1 trading plan. |
| 05/15/2024 | Date of stock sale transaction. |
| 05/17/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.